Merck KGaA of Darmstadt, Germany, agreed to buy Rapid Micro Biosystems for $0.75 per share in cash, the companies announced on November 16, 2026. Rapid Micro makes equipment that automates microbial quality-control testing for pharmaceutical manufacturers. The companies expect the deal to close in December, subject to a majority tender condition and other closing requirements. Merck KGaA announcement · Rapid Micro announcement
Rapid Micro separately reported $9.5 million of third-quarter 2026 revenue, up 22% year over year, and a gross margin of 25%, up 16 percentage points. It placed seven Growth Direct systems during the quarter. Rapid Micro’s third-quarter results
Why it matters
OX8 analysis. The deal would give Merck KGaA another product to sell through its life-science business. A measure of the deal’s value will be whether Merck’s distribution network helps increase system placements and the product and service sales that follow.
What to watch
Rapid Micro said the tender offer had yet to start when the deal was announced. The next milestones are the buyer’s Schedule TO and Rapid Micro’s Schedule 14D-9, followed by whether enough shares are tendered for the deal to close. Tender offer disclosures


Leave a Reply